Rangering i aksjer
#24449
Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology... Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology firm dedicated to advancing innovative immunotherapies for cancer treatment. Its primary drug candidate, LTX-315, is an oncolytic molecule currently undergoing Phase II clinical trials. This therapy is formulated for intratumoral injection, aiming to provide localized treatment for solid tumors. Additionally, Lytix Biopharma is developing LTX-401, another oncolytic molecule in its preclinical phase, specifically designed to target deep-seated cancerous lesions, including those found in liver cancer. The company was established in 2003.
Handel Lytix Biopharma AS (LYTIX)
Pris LYTIX pris med markedsverdi på B
Markedsverdi av Lytix Biopharma AS(LYTIX)
Markedsverdi: $60.45M
Per August 2026 har Lytix Biopharma AS en markedsverdi på $60.45M. Dette gjør Lytix Biopharma AS til det 24449th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Lytix Biopharma AS fra 2021 til 2026
LYTIX sammenlignet med topp 5 mest populære stocks
| Pris på LYTIX |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.225T
|
+8,643,803.49%
|
|
|
|
|
$4.567T
|
+7,554,793.23%
|
|
|
|
|
$4.156T
|
+6,874,728.45%
|
|
|
|
|
$3.606T
|
+5,964,437.34%
|
|
|
|
|
$2.782T
|
+4,601,788.39%
|
